Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers find potential celebrex target in lung cancer

15.07.2005


A product produced by lung cancer tumors fuels the cells that suppress immune function in patients and may be a target for Celebrex therapy, giving oncologists another weapon to fight cancer, according to a study by researchers at UCLA’s Jonsson Cancer Center.



Researchers found that PGE2, which is produced normally by epithelial cells but at very high levels in lung cancer and other malignancies, up-regulates the activity of lymphocytes called T-regulatory cells, which suppress immune function, making it even harder for a patient to fight cancer. For the first time, UCLA researchers showed that PGE2 increases the growth and function of T-regulatory cells, making them more effective immune suppressors, said Dr. Steven Dubinett, director of the Lung Cancer Research Program at UCLA’s Jonsson Cancer Center and senior author of the study.

The study appears in the July 15, 2005, issue of the peer-reviewed Journal of Immunology.


"We know that COX-2 inhibitors like Celebrex decrease PGE2, so when we discovered that PGE2 was fueling the T-regulatory cells, we knew we had a therapy we could test," said Dubinett, also a professor of pulmonary and critical care medicine and director of the Specialized Program of Research Excellence (SPORE) in lung cancer. "This discovery opens up the possibility that we could utilize relatively non-toxic drugs to augment immune responses in cancer patients."

The COX-2 inhibitors could be given with chemotherapy and immunotherapy drugs to help boost immune function in patients and help them to better fight cancer, Dubinett said.

Dubinett and his research team had hypothesized that PGE2 might be involved in suppression of the immune system. They first tested the theory in animal models and found that PGE2 was fueling the growth and function of the T-regulatory cells. Using Celebrex, researchers were able to decrease in number and function the T-regulatory cells by blocking PGE2. That study appeared in the June 15 issue of the peer-reviewed journal Cancer Research.

Dubinett and his team then validated their work in human cancer cell lines, the basis of the Journal of Immunology study. Again, administration of Celebrex decreased the number and function of T-regulatory cells, providing a boost to the immune system.

"Our data indicate that regulation of PGE2 production may in turn modulate T-regulatory cell development and function," the study states. "These findings suggest new therapeutic strategies targeting PGE2 in the prevention and treatment of cancer."

UCLA is launching a pilot study led by Dr. Karen Reckamp, an assistant professor of hematology/oncology, to further test their findings. Reckamp is seeking 24 patients with advanced lung cancer to participate in the study. Patients would take Celebrex for a week so researchers can study the drug’s affect on the T-regulatory cells. Patients would give blood before taking Celebrex and after the week-long course of therapy, Reckamp said, giving researchers a clue as to whether the drug will function in humans the way it has in cell and animal models.

For more information on the study, call 310-825-5688.

Dubinett said the clinical research study being conducted by Reckamp will begin to provide important information by determining if this therapy can contribute to augmenting immune responses in patients with lung cancer.

"If this research holds true in patients, it could provide a new avenue for using this drug in combination with other therapies to fight lung cancer," he said.

UCLA’s Jonsson Comprehensive Cancer Center is made up of more than 240 cancer researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation’s largest comprehensive cancer centers, the Jonsson Cancer Center is dedicated to promoting cancer research and translating the results into leading-edge clinical studies. In July 2005, the Jonsson Cancer Center was named the best cancer center in the western United States by U.S. News & World Report, a ranking it has held for six consecutive years.

Kim Irwin | EurekAlert!
Further information:
http://www.mednet.ucla.edu

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

What the world's tiniest 'monster truck' reveals

23.08.2017 | Life Sciences

Treating arthritis with algae

23.08.2017 | Life Sciences

Witnessing turbulent motion in the atmosphere of a distant star

23.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>